88 results about "IGF-Binding Proteins" patented technology

New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.

The present invention provides non-invasive methods for detecting, monitoring, staging, and diagnosing malignant melanoma in a skin sample of a subject. The methods include analyzing expression in skin sample of one or more melanoma skin markers. The melanoma skin markers include IL-1 RI, endothelin-2, ephrin-A5, IGF Binding Protein 7, HLA-A0202 heavy chain, Activin A (βA subunit), TNF RII, SPC4, and CNTF Rα. The skin sample can include nucleic acids, and can be a human skin sample from a lesion suspected of being melanoma.

New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium / calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

The present invention relates to screening or testing for insulin like growth factors, insulin like growth factor binding proteins and / or acid labile subunit by the use of a solid support. Blood is collected onto a solid support, such as paper, and subsequently the analytes of interest are extracted for testing.

A conjugate consisting of insulin-like growth factor binding protein 4 (IGFBP-4) and one or two polyethylene glycol) group(s), said polyethylene glycol) group(s) having an overall molecular weight of from about 30 to about 40 kDa is disclosed. This conjugate is useful for the treatment of cancer.

The present invention features methods of modulating primary stem cell differentiation in culture by altering the endogenous activity of an insulin-like growth factor.

The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-enoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, use of the protein to produce antibodies capable of binding specifically to the protein, methods for screening for pathologies in pregnant and non-pregnant patients that are based on detection of PAPP-A2 antigen in human body fluids or PAPP-A2-encoding nucleic acid molecules, use of the protein to screen for agents that alter the protease activity of PAPP-A2, use of the protein as a therapeutic target for such agents, and use of the protein as a therapeutic agent in relevant pathological states. Methods for screening for altered focal proliferation states in pregnant and / or non-pregnant patients, which include detecting levels of PAPP-A2, are also described. The present invention also provides the identification of a natural substrate of PAPP-A2, insulin-like growth factor binding protein (IGFBP)-5.

The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.

The invention provides an SNP locus related to growth characteristics of patinopecten yessoensis. The locus is the 1054 site of IGFBP (Insulin Like Growth Factor Binding Proteins) genes of which the nucleotide sequence is shown as SEQ ID NO:2 and has the base of A or G. The invention also provides a probe for detecting the SNP locus and a parting primer. The transcription sequence of the IGFBP genes in the patinopecten yessoensis is subjected to sequencing and Clustal comparison, and three SNP loci are screened. The site polymorphism is detected in the patinopecten yessoensis group by using a high resolution melting curve technology, and correlation between the site genotype frequency and the growth characteristics of patinopecten yessoensis is analyzed. The locus C.1054A>G is obviously related to important growth characteristics such as the height, shell length, weight, soft weight and adductor muscle weight of the patinopecten yessoensis, the growth characteristics of the AG type individuals are obviously lower than those of AA and GG type individuals (P is less than 0.05), and the characteristic value of the GG type is the highest. Therefore, individuals of which the genotype is GG on the locus can be preferentially selected during production and are used as parents for performing high-yield patinopecten yessoensis breeding or performing large-scale breeding.

Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.

New markers for diseased liver conditions have been identified. A combination of protein C (PROC) and retinol binding protein 4 (RBP4) in blood are biomarkers to distinguish patients at different stages of hepatic fibrosis due, for example, to chronic infection with hepatitis C virus (HCV). Also, alpha-1-B glycoprotein (A1BG), complement factor H (CFH) and insulin-like growth factor binding protein acid labile subunit (IGFALS) distinguish subjects with chronic or acute liver conditions such as hepatitis infection or liver fibrosis from healthy controls.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

The invention relates to the field of medical science, and provides a biomarker for hepatocellular carcinoma related detection, particularly a biomarker for detecting HBV related hepatocellular carcinoma. The biomarker comprises an insulin-like growth factor binding protein 7 (IGFBP7) and an alpha fetoprotein (AFP). A method for detecting hepatocellular carcinoma, based on the biomarker namely the IGFBP7 and the AFP, comprises a step of carrying out judgement by measuring a marker IGFBP7 gene promotor methylation level and detecting the sensitivity of the marker AFP for being combined with serum IGFBP7 gene promoter methylation. According to biomarker, the AFP is combined with the IGFBP7 gene promoter methylation, so that the traditional detection of single indexes is changed, and the efficiency of HCC diagnosis is increased.

An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and / or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and / or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury) / ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI / ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.

The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor / insulin-like-growth-factor-binding-protein-complex.

The invention provides a tumor diagnosis reagent or kit based on detection of an IGFBP-2 (insulin-like growth factor binding protein 2) autoantibody or combined detection of the IGFBP-2 autoantibody IGFBP-2. The tumor diagnosis reagent or kit comprises a first reagent group capable of detecting the IGFBP-2 autoantibody in a detected sample, or a first reagent group capable of detecting the IGFBP-2 autoantibody in the detected sample and a second reagent group capable of detecting IGFBP-2 in the detected sample. The invention also provides application of IGFBP-2 autoantibody detection or combined detection of the IGFBP-2 autoantibody and the IGFBP-2 in preparing the tumor diagnosis reagent or kit. Detection of the IGFBP-2 autoantibody can be used for diagnosing early-phase tumor or high-grade adenoma with cancerization risk, in particular for diagnosing prometaphase glioma and high-grade colorectal polyp and / or colorectal neoplasms of I-II grades with cancerization risk; and the combined detection of the IGFBP-2 autoantibody and the IGFBP-2 can be used for diagnosing tumors of different grades and monitoring each phase of a tumor from low grade to high grade, such as diagnosing and identifying astrocytoma, anaplastic astrocytoma and / or spongioblastoma, as well as I-IV grades of colorectal neoplasms.

The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.

The invention discloses an application of insulin-like growth factor binding protein 5 (IGFBP5) in promotion of mesenchymal stem cell induced periodontal tissue regeneration.

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

The invention relates to a joint inspection kit for pregnant woman premature birth fetus fibronectin and phosphorylation insulin-like growth factor binding protein-1, and belongs to the technical field of inspection kits. The kit comprises a substrate, wherein a nitrocellulose membrane is arranged on one side of the substrate; a binding pad is arranged at the front end of the nitrocellulose membrane; a plurality of arrow tags are arranged at the rear end of the binding pad; a first non-transparent protection pad is arranged behind the arrow tags; a first detection line is arranged behind the first non-transparent protection pad; a mass control line is arranged behind the first detection line; a second first non-transparent protection pad is arranged at the rear end of the nitrocellulose membrane. A second detection line is further arranged between the first detection line and the mass control line. The kit is simple and convenient to apply, can be used for further improving the accuracy in premature birth diagnosis, and is applicable to large-scale popularization and application as joint inspection result provides a powerful basis for next accurate treatment.

The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In certain embodiments, the invention relates to non-covalent binding interactions between insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs).

The invention relates to the field of bio-detection and particularly relates to a detection kit for quantitatively detecting an insulin-like growth factor binding protein-1, a preparation method and use thereof. The detection kit for the insulin-like growth factor binding protein-1 provided by the invention comprises a test paper card which comprises a bottom plate as well as a sample pad, a gold label pad, a nitrocellulose membrane and a water absorption pad which are sequentially arranged from a sampling end on the surface of the bottom plate; the gold label pad comprises an insulin-like growth factor binding protein-1 antibody, a detection line and a quality control line are coated on the nitrocellulose membrane, and the insulin-like growth factor binding protein-1 antibody on the gold label pad is labeled by using a fluorescent microsphere. The kit provided by the invention can be used for detecting the insulin-like growth factor binding protein-1 by virtue of a fluorescent microsphere immunochromatography technology for the first time, has sensitivity and specificity and has the advantages of fast, simple and convenient operation, accurate result, economical benefit and practicality and the like.

The invention relates to an induced expression and purification method of a human-derived insulin-like growth factor binding protein 1 in pichia pastoris. A nucleotide sequence optimized by codons and used for coding the human-derived insulin-like growth factor binding protein 1 is connected with an HIS tag label, then is constructed into a pichia pastoris induced expression vector, next is transferred into pichia pastoris, and is subjected to induced expression; the expression product is subjected to affinity chromatography to obtain a purified human-derived insulin-like growth factor binding protein 1. The invention also relates to related antibodies and an application thereof in preparation of diagnostic kits for premature rupture of fetal membranes. The induced expression and purification method of the human-derived insulin-like growth factor binding protein 1 in pichia pastoris is skillful in design, and thus the human-derived insulin-like growth factor binding protein 1 can be efficiently expressed; and with the human-derived insulin-like growth factor binding protein 1 as an antigen, a high-specific polyclonal antibody and a high-specific monoclonal antibody for recognition of different IGFBP-1 epitopes are obtained, thereby laying the foundation for application of multiple downstream detection kits, and being suitable for large-scale popularization and application.

Disclosed are compositions and methods useful in the regulation of cell proliferation. The invention provides TGF-β (transforming growth factor β) and IGFBP-3 (insulin like growth factor binding protein 3) as ligands that engage LRP (low density lipoprotein receptor-related protein), heretofore known as TβR-V (TGF-β receptor V) and IGFBP-3 receptor, to effect a change in the phosphorylation and activation status of IRS (insulin receptor substrate) proteins. Compositions comprising TGF-β or IGFBP-3 and LRP or IRS protein are useful in the inhibition of cell proliferation and in the treatment of various diseases associated with unregulated cell proliferation.